Welcome to edition #32. Here is what happened across the health and life science industry in the last two weeks through an operator lens. Every story links straight to the original source, so You can go as deep as You want.
Two threads run through these two weeks. The first is how consumer health features get packaged and paid for. Google launched a new tracker alongside a data partnership with Flo, Ultrahuman added a free heart rhythm check alongside its paid overnight monitoring, and Withings now charges new customers for automatic app syncing.
The second is how AI and prices reach the patient. Utah announced supervised pilots in which AI prescribes or renews some medications, and a group of US states sued OpenAI over alleged harms from ChatGPT, including dangerous medical advice. On prices, Epic plans a tool that shows cash prices before a prescription is sent, and the FTC warned large health systems that missing prices can mislead patients. Here is everything in detail.
The 30-Second Skim
Google launches the Fitbit Edge and a Flo partnership. The tracker goes on sale October 27, and Flo says Google also invested. (Wearables & Consumer Health)
Biohub’s AI biology initiative grows to 1.8 billion dollars. New money comes from the US Energy Department and three tech companies; the rest is earlier commitments and data. (AI in Health)
Eight US states sue OpenAI. Their claims include dangerous medical advice from ChatGPT. (AI in Health)
Lilly’s weight-loss pill moves closer to the EU market. The EMA’s drug committee recommended Foundayo. (Life Sciences & Biopharma)
Epic plans to show cash drug prices in the doctor’s office. The FTC also warned 24 large health systems about missing prices. (MedTech & Infrastructure)
⌚ Wearables & Consumer Health
🚀 Google launches the Fitbit Edge, a 179.99 dollar tracker with an ECG app.
Preorders opened on October 12, and the tracker goes on sale on October 27, Google says. The ECG app works only in select countries and not for people under 22. Health Guardian features and the Google Health Coach need a paid Google Health Premium subscription, with three months included.
Read more → Google · 9to5Google · Fierce Healthcare
💰 Google Health signs a multi-year partnership with women’s health app Flo, which says Google also invested.
Announced on October 12, the deal lets users who opt in link their Flo cycle data with the Google Health app from early 2027. Google says the data will never be used for ads or sold, and puts Flo’s users at more than 80 million women a month. Flo says Google also invested, without disclosing an amount.
Read more → Google · MobiHealthNews · Fierce Healthcare
🚀 Oura rolls out blood pressure signals and GLP-1 tracking in more than 30 new markets, including the EU.
Starting October 6 and over several weeks, members with a Gen3 ring or newer in the EU, the UK, Canada, Australia and other countries get the features, Oura says. They include overnight blood pressure patterns, a 30-day view of breathing during sleep and a log for GLP-1 doses and side effects. Oura calls them wellness features that do not diagnose disease.
Read more → Oura · Wareable · ChannelNews
🚀 Ultrahuman adds a free 60-second check for atrial fibrillation to its Ring AIR and Ring PRO.
Since October 7, owners in supported markets in the UK, Europe, the Middle East and Asia-Pacific can run Heart Scan, which uses CE-marked software from FibriCheck to flag possible atrial fibrillation, a common heart rhythm problem, the company says. Each scan creates a report to share with a doctor. Overnight monitoring costs 4.90 pounds or 5.90 euros a month.
Read more → Ultrahuman · Wareable · ChannelNews
🚀 Withings makes new customers pay for Withings+ to sync automatically with Apple Health and other apps.
For accounts created from October 13, automatic sync to third-party apps is part of the paid Withings+ plan, Withings confirmed on October 15. MacRumors puts the US price at 99.50 dollars a year. Older accounts keep free sync, and CSV or PDF exports stay free for everyone, the company says.
Read more → Withings Community (staff reply) · MacRumors · Engadget
🔬 An NEJM trial finds glucose sensors improve blood sugar control in type 2 diabetes without insulin.
In the CONNECT trial, first presented in June and published on October 14, 283 adults at 22 US primary care practices used a continuous glucose sensor or routine care for six months. Blood sugar improved more with the sensor, and users spent about five more hours a day in their target range. Dexcom funded the trial.
Read more → NEJM · Fréquence Médicale · MD+DI
💰 London startup Sava raises a reported 36 million dollars in a round led by glucose meter maker Ascensia.
Announced on October 9, the deal also makes Ascensia the exclusive distributor of Sava’s sensor, starting in Europe. Sava says its sensors are about ten times shorter than those in today’s continuous glucose monitors. The sensor is not yet approved; Sava aims for European approval and launch within 18 to 24 months.
Read more → Ascensia · EU-Startups · Tech Funding News · MD+DI
🤖 AI in Health
💰 Biohub grows its AI biology effort to 1.8 billion dollars in money, data and computing power.
Biohub, the science group of Priscilla Chan and Mark Zuckerberg, said on October 7 that US agencies, Google DeepMind, Isomorphic Labs and Meta are joining its Virtual Biology Initiative. The Energy Department adds more than 500 million dollars over five years and the three tech companies 300 million dollars together; the rest is Biohub’s own 500 million dollars from April and existing NIH data.
Read more → Biohub · Axios · Medical Economics
💰 Isomorphic Labs is reportedly in talks to raise money at a valuation of at least 40 billion dollars.
Bloomberg reported on October 8 that the AI drug discovery company led by Demis Hassabis is in early talks, and one source said the value could reach 50 billion dollars. Nothing has closed and terms could change, according to the report. The Google DeepMind spinout raised 2.1 billion dollars about five months earlier.
Read more → Bloomberg
🔬 A JAMA study counts about 950,000 US clinicians using OpenEvidence, and Johns Hopkins signs on as a partner.
The study, published October 15, found that these clinicians asked the AI tool about 271 million questions between January 2024 and June 2026; several of its authors worked for OpenEvidence. On October 13, Johns Hopkins Medicine and OpenEvidence announced a partnership on AI for patient care and medical training, with the specific tools still to be defined.
Read more → JAMA · Johns Hopkins Medicine · Fierce Healthcare · TechTarget
⚖️ Eight US states sue OpenAI, alleging ChatGPT gives dangerous medical advice and harms children.
The attorneys general of Arizona, Arkansas, Idaho, Iowa, Kansas, Montana, Nebraska and West Virginia filed separate consumer protection lawsuits in state courts on October 14. They allege that OpenAI marketed ChatGPT as safe while hiding risks such as dangerous medical advice and coaching people toward suicide or violence. OpenAI says it has built child safety protections into ChatGPT.
Read more → Arizona complaint · AP via Fortune · Just Security · KCTV5
⚖️ Utah announces pilots in which AI prescribes acne creams and renews routine long-term medications.
Utah announced the pilots on October 5 under its AI sandbox, a temporary exception from licensing rules. Nolla Health may prescribe acne creams and gels to adults, and August AI may refill long-term medications from a fixed list once its pilot starts. At first, two doctors check every Nolla prescription and a licensed clinician checks August’s first 250 refills.
Read more → Utah Department of Commerce · Deseret News · Healthcare Dive
🔬 The Lancet publishes a study in which Google’s chatbot AMIE interviews patients before doctor visits.
Researchers from Google and Beth Israel Deaconess Medical Center published the Alphabet-funded study on October 8. At one clinic, 98 adults chatted by text with AMIE before an urgent family doctor appointment while doctors watched every conversation live. None had to be stopped for safety reasons, supervisors noted one made-up detail, and the authors call for larger trials.
Read more → The Lancet · Google · Unite.AI · Neoteo
💰 Suki raises 90 million dollars to build AI agents that handle tasks after a doctor visit.
Suki, which makes an AI assistant that writes clinical notes during patient visits, announced the round on October 13. CEO Punit Soni says the new agents will take on work such as referrals and insurance approvals for new medications. The company says it works with more than 250 healthcare organizations.
Read more → Healthcare Dive · Fierce Healthcare
⏳ Longevity & Healthy Aging
🔬 A large immune cell atlas shows that people’s immune systems age along two different paths.
In Immunity on October 9, researchers at Washington University in St. Louis described millions of immune cells from over 2,600 mostly healthy adults. In UK data on about 50,000 people, a blood protein pattern tied to one type of killer immune cell went along with higher risks of death and diseases like type 2 diabetes over the next decade. The lab is developing a simple blood test, not yet available.
Read more → Immunity · WashU Medicine · GEN · Live Science
🔬 Large and male dogs age faster at the molecular level, a new DNA-based clock shows.
In a Science study published October 8, Arizona State University researchers built an epigenetic clock, a DNA-based age estimate, from the blood of nearly 900 dogs. Large and male dogs, which tend to live shorter lives, aged faster on it. Dogs whose molecular age ran ahead of their real age were more likely to die.
Read more → Science · Arizona State University · Live Science · GEN
🔬 The supplement nicotinamide riboside does not help people with early Parkinson’s disease, a large Norwegian trial finds.
In a trial at 11 centers in Norway, published in JAMA on October 8, 410 people with early Parkinson’s took the supplement or a dummy pill for a year. Symptoms did not improve on the supplement and worsened slightly more than on the dummy pill, though the difference was small. The researchers advise against NAD-boosting supplements for Parkinson’s outside controlled studies.
🧬 Life Sciences & Biopharma
⚖️ EU drug committee recommends approving Lilly’s weight-loss pill Foundayo.
On October 16, the European Medicines Agency’s drug committee recommended Foundayo (orforglipron), a once-daily GLP-1 pill, for adults with obesity or overweight plus a weight-related health problem, and for type 2 diabetes. The tablet can be taken at any time of day, with or without food. The European Commission still has to decide.
Read more → EMA · PharmExec · Life Science Focus
⚖️ EU drug committee recommends Revolution Medicines’ pill Rasonque for advanced pancreatic cancer.
On October 15, the European Medicines Agency’s drug committee recommended Rasonque (daraxonrasib) for adults whose pancreatic cancer has spread and worsened after earlier treatment. In a large trial, patients on the pill typically lived about a year, versus just over half a year on chemotherapy. The European Commission still has to decide; the drug has been approved in the US since August.
Read more → EMA · pharmaphorum · AJMC
🔬 Three scientists win the 2026 Nobel Prize in Medicine for switching nerve cells on and off with light.
On October 5, the Nobel Assembly at Karolinska Institutet honored Karl Deisseroth of Stanford, Peter Hegemann of Humboldt University of Berlin and Georg Nagel of the University of Würzburg. Their method, optogenetics, lets labs control single nerve cells with light, and clinical trials are testing it to restore some sight in blind people.
Read more → Khaleej Times · Al Jazeera · South China Morning Post
🔬 Gene therapy with light goggles helps some blind people detect light and objects again, a small study shows.
The NEJM study, published October 8, treated ten people blinded by retinitis pigmentosa, an inherited eye disease, with one eye injection that makes retinal cells react to light, plus goggles that activate them. Seven of the ten became more sensitive to light. GenSight Biologics, which develops the therapy, funded the small safety study; most side effects were mild, and the therapy is not approved.
Read more → NEJM · Retinal Physician · News-Medical
💰 Dutch investor Forbion raises 2.3 billion euros for biotech, its largest fundraise to date.
On October 6, Forbion said it raised 2.3 billion euros, about 2.6 billion dollars, across two new funds. Backers include Eli Lilly and Germany’s KfW Capital, and the money is meant to support about 30 young biotech companies.
Read more → Forbion · Fierce Biotech · BioPharma Dive
🔬 BioNTech’s mRNA cancer therapy misses the first main goal of a head and neck cancer trial.
On October 13, BioNTech said BNT113, added to the cancer drug Keytruda as a first treatment, did not slow HPV-linked head and neck cancer more than Keytruda alone in a first analysis. Independent monitors advised continuing the trial to see whether patients live longer; under its design, a clear survival benefit would still make it a success, BioNTech says.
Read more → BioNTech · BioSpace · BioPharma Dive
🏥 MedTech & Infrastructure
🚀 Epic plans a marketplace that lets patients compare pharmacy cash prices in the doctor’s office.
Epic announced Prescription Marketplace on October 15. Before a prescription is sent, doctors and patients at health systems using Epic will see cash prices from Amazon Pharmacy, Mark Cuban Cost Plus Drugs, Costco and Eli Lilly’s LillyDirect next to the insurance price. Epic plans the release for summer 2027.
Read more → Epic · Fierce Healthcare · Healthcare IT News
⚖️ FTC warns 24 large US health systems that missing or incomplete prices can mislead patients.
FTC Chairman Andrew Ferguson sent letters on October 5 to 24 of the largest US health systems, which the agency did not name. Not showing prices, or leaving out doctor or facility fees, may break consumer protection law even when hospitals follow federal price rules, the letters say. They are warnings, not findings that any hospital broke the law.
Read more → FTC · Becker’s Hospital Review · Healthcare Dive · TechTarget
💰 General Medicine, from PillPack co-founder TJ Parker, raises 120 million dollars to sell care with upfront prices.
On October 6, General Medicine announced a Series B round of 120 million dollars led by Andreessen Horowitz, with Eli Lilly and Mercy Health among the investors. Its online store shows insurance and cash prices for prescriptions, lab tests, virtual visits and other care before people buy.
Read more → General Medicine · Fierce Healthcare · MobiHealthNews
💰 Stryker agrees to invest about 400 million dollars in CMR Surgical, with an option to buy it.
On October 12, Stryker agreed to put about 400 million dollars into CMR Surgical, the British maker of the Versius surgical robot, and got the exclusive right to buy the whole company later. The deal still needs regulatory approval. In the US, where Versius is so far cleared for gallbladder removal, only Stryker will sell it; CMR keeps selling it elsewhere.
Read more → Stryker · MedTech Dive · MD+DI
💰 Siemens Healthineers stops selling general ultrasound systems and focuses on imaging during heart procedures.
Since October 12, the company no longer sells general imaging ultrasound systems such as Acuson Sequoia, Redwood, Juniper and Maple. It keeps selling ultrasound used during heart procedures, such as a catheter with an ultrasound tip that images from inside the heart. Existing customers keep getting maintenance, software updates and probes, the company says.
Read more → Siemens Healthineers · MedTech Dive · AuntMinnie
🚀 Centene plans to let more than 160,000 providers skip waiting for its approval on some outpatient care.
Centene said on October 13 that a nationwide gold card program starts in November for select outpatient services. Qualifying providers can treat patients without waiting for prior authorization, the insurer’s OK before treatment, but must still notify Centene first. UnitedHealthcare and Humana run similar programs, Healthcare Dive reports.
Read more → Centene · Healthcare Dive · Fierce Healthcare
What This Means
For anyone building in consumer health, several stories here tie the device to a paid plan or a data partnership: Google’s Premium plan and its Flo partnership, Ultrahuman’s paid overnight monitoring and Withings’ paid app syncing for new customers. What users pay for, and which data they agree to share, becomes part of the product, not a footnote.
In health AI, the last 2 weeks show growth and accountability questions side by side. OpenEvidence’s reach among clinicians and Suki’s new funding sit next to Utah’s supervised pilots and the state lawsuits against OpenAI, which both raise the question of who stays accountable. Prices show a similar split: Epic and General Medicine build tools that show prices before care is chosen, while the FTC warns hospitals that missing prices can mislead patients.
For healthy aging, measuring and proving are different steps. This edition brings new ways to read aging in dogs and in human immune cells, while a NAD-boosting supplement did not help people with early Parkinson’s.
The one newsletter you need to understand what moved across Health & Life Science and what it means.
Before You Go
If this saved You time this week, forward it to one person who needs to stay current on health and life science.
Reply with one line: what did I miss? The best newsletters are built with their readers.
And if Your team wants this market intelligence translated into strategy, a workshop or a board-level sparring session, that is exactly what the www.venture-institute.com does.
Healthcare Minutes is part of www.health-guy.com. Written by Leonard Rinser.